Presentations 2017

SHM’s staff give presentations on several occasions throughout the year with findings from research and papers presented at conferences worldwide. The most recent presentations given in 2017 are listed below.

Oral presentations

The HIV epidemic in the Netherlands: an update
Reiss P

Many introductions but little transmission of HIV 1 non B subtypes in the Netherlands
Bezemer D, Hall M, van Sighem A, Reiss P, Fraser C, Ratmann O

Estimating HIV incidence and the undiagnosed HIV population in the European Union/European Economic Area
van Sighem A, Pharris A, Quinten C, Noori T, Amato-Gauci A.J. and the ECDC HIV/AIDS Surveillance and Dublin Declaration Networks

Geospatial analysis and mapping of new HIV diagnoses, late presentations and GP testing practices in Amsterdam
Böhnke L, Vu T, van Bergen J, van Sighem A, Groot Bruinderink M, Op de Coul E, Kroone M, Reiss P, Heidenrijk M, de Bree GJ

Cost-effectiveness of increased HIV testing among men who have sex with men in the Netherlands
Reitsema M, Steffers L, Wallinga J, van Benthem B, Visser M, de Munnik S, van Sighem, Schim van der Loeff M, Xiridou M, Mangen MJM

Poster presentations

The impact of immediate initiation of combination antiretroviral therapy on the HIV epidemic among MSM
Reitsema M, Wallinga J, van Benthem B, van Sighem A, Schim van der Loeff M, Xiridou M

Differences in access to HIV testing, treatment and healthcare among nonmigrants and migrants living with HIV in the Netherlands: a cross-sectional study*
Bil JP, Zuure FR, Alvarez-del Arco D, Prins J, Brinkman K, Leyten E, van Sighem A, Burns F, Prins M

Oral presentations

Living positive with HIV: A randomized controlled trial of a guided Internet-based self-help intervention for people with HIV and depressive symptoms.
Van Luenen S, Kraaij V, Spinhoven P, Garnefski N. 

Oral presentations

The hepatitis C continuum of care among HIV infected individuals in EuroSIDA 
Amele S, on behalf of EuroSIDA

HIV and ageing: using cohort data to separate the myths from reality
Van Zoest R, Schouten J

Use of integrase inhibitors is an independent risk factor for immune reconstitution inflammatory syndrome (IRIS) in HIV-1 late presenters: An ATHENA Cohort Study
Wijting I

Poster presentations

Abacavir usage patterns and hypersensitivity reactions (HSR) in the EuroSIDA cohort
A. Roen, K. Laut, A. Pelchen Matthews, E. Borodulina, L. Caldeira, A. Clarke, B. Clotet, A. d'Arminio Monforte, G. Fätkenheuer, J. M. Gatell Artigas, I. Karpov, A. Kuznetsova, G. Kyselyova, I. Mozer-Lisewska, F. Mulcahy, L. Ragone, A. Scherrer, V. Uzdavin

Estimating the country-specific burden of late presentation to HIV care across Europe between 2010-2014
Kamilla Laut on behalf of the Late Presentation Working Group in the COHERE and EuroSIDA studies.

Occurrence of hypersensitivity reaction and hepatotoxicity in patients receiving integrase inhibitors: Results from the EuroSIDA study 
L. Shepherd, L. Peters, J. Begovac, T. Benfield, L. Curtis, S. De Wit, A. Horban, E. Jablonowska, M. Johnson, I. Khromova, M.H. Losso, J. Lundgren, L.N. Nielsen, D. Raben, A.L. Ridolfo, B. Schmied, C. Stephan, A. Thalme, V. Vannappagari, I. Yust, O. Kirk

Discontinuation of dolutegravir- and elvitegravir-containing cART in The Netherlands; incidence rates and risk factors
PDJ Bollen, CS Hakkers , TS Boender, R van Crevel, A Brouwer, AIM Hoepelman, P Reiss, FWNM Wit, JE Arends, DM Burger, on behalf of the ATHENA national observational HIV cohort

Oral presentations

Estimating HIV incidence and the undiagnosed HIV population in the European Union / European economic area
van Sighem AI

HIV-1 infection and sexual functioning among middle-aged men who have sex with men 
Dijkstra M, van Lunsen RHW, Kooij KW, Davidovich U, van Zoest RA, Wit FWMN, Prins M, Reiss P, Schim van der Loeff MF, on behalf of the AGEhIV cohort study

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle- and high-income countries Anderegg N, Kirk O, for the IeDEA & COHERE collaborations 

Pre-exposure prophylaxis (PrEP) among men who have sex with men in the Netherlands: motives to choose for, switch to, or stop with daily or event-driven PrEP Zimmermann HML, Eekman SW, Achterbergh RCA, Prins M, Schim van der Loeff MF, de Vries HJC, Hoornenborg E, Davidovich U, on behalf of AMPrEP in H-TEAM

Closing the gaps: lessons learned in Amsterdam’s success in reaching 90-90-90 
Prins M, on behalf of the HIV Transmission Elimination Amsterdam initiative


Poster presentations

From HIV infection to HIV suppression: improvements in the time to reach successive stages in the HIV care continuum in the Netherlands
van Sighem AI

Initiation of cART: a nationwide overview of variation between HIV treatment centres in the Netherlands
Boender TS

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: results from the D:A:D study 
Boyd MA, Mocroft A, Ryom L, d’Arminio Monforte A, Sabin C , El-Sadr W, Hatleberg CI , De Wit S, Weber R, Fontas E, Phillips A, Dabis F, Reiss P, Lundgren J, Law M , D:A:D Study Group 

People living with HIV and HIV-negative individuals with similar lifestyles show greater age advancement compared to healthy blood donors
De Francesco D , Oehlke S , Bürkle A, Wit FW, Franceschi C, Kootstra NA , Libert C, Grune T, Weber D ,  Jansen EHJM, Reiss P , Sabin CA , for the Co-morBidity in Relation to Aids (COBRA) Collaboration

The application of artificial intelligence to predict response to different HIV therapies, without a genotype: new models for therapy optimisation in resource-limited settings  
Revell A, Hamers R, Morrow C, Wood R , Reiss P, van Sighem A, Johnson M, Ruiz L, Alvarez-Uria G , Sierra-Madero J, Montaner J , Lane HC, Larder B, RDI Data and Study Group  

International trends in new HIV diagnoses among men who have sex with men in North America, Western Europe and Australia 2000-2014
Chapin-Bardales J, Sullivan PS, Guy RJ, Kaldor J, McGregor S, Sasse A, Archibald C, Rank C, Casabona Barbarà J, Folch-Toda C, Vives Martin N, Cowan SA, Cazein F, Velter A, an der Heiden M, Gunsenheimer-Bartmeyer B, Marcus U, Op de Coul ELM, Van Sighem A, Aldir I, Cortes Martins H, Berglund T, Velicko I, Gebhardt M,  Schmidt AJ, Delpech V, Hughes G, Nardone A, Hall HI, Johnson AS

Oral presentations

Unrestricted DAA access in the Netherlands: rapid uptake of treatment in HIV/HCV+ patients in the Netherlands [Onbeperkte DAA toegang in Nederland: snelle opname van behandeling in HIV/HCV+ patiënten in Nederland]
Smit C

Oral presentations

Estimating HIV incidence and the undiagnosed HIV population in the European Union/European Economic Area
Sighem A, Pharris A, Quinten C, Noori T, Amato-Gauci A, on behalf of The European Surveillance System HIV/AIDS database.

Poster presentations

Initiation of cART: a nationwide overview of variation between HIV treatment centres
Smit C

Durability of first-line combination antiretroviral therapy (cART) for HIV in the Netherlands
Boender TS

Oral presentations

Estimating HIV incidence with the ECDC HIV Modelling Tool
Van Sighem A

Oral presentations

Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D study
Shepherd L, Ryom L, Petoumenos K, Hatleberg CI, d'Arminio Monforte A, Bonnet F, Reiss P, Lundgren JD, Mocroft A

Cardiovascular prevention policy in HIV: Recommendations from a modelling study
van Zoest R, Smit M, Nichols B, Vaartjes I, Smit C, van der Valk M, Wit F, Hallett TB, Reiss P

Association between cardiovascular disease and contemporarily used protease inhibitors
Ryom L, Lundgren JD, El-Sadr WM, Reiss P, Phillips A, Kirk O, Weber R, Sabin C, Mocroft A

Unrestricted DAA access in the Netherlands: rapid therapy uptake in HIV+HCV+ patients
BoerekampsA, Newsum A, SmitC, Reiss P, RichterC, van der ValkM, ArendsJ, BrinkmanK, RijndersB

Body mass index and the risk of serious non-aids events: the D:A:D study 
Achhra AC, Sabin C, Ryom L, d'Arminio Monforte A, de Wit S, Phillips A, Pradier C, Lundgren JD, Law M


Poster presentations

Stopping secondary TE prophylaxis in suppressed patients with CD4 100-200 is not safe
Miro JM

Darunavir/r use and incident chronic kidney disease in HIV-positive persons
Ryom L, LundgrenJD, Reiss P, Kirk O, LawM, Ross M, Morlat P, Fux CA, Mocroft A

Earlier diagnosis and treatment reduces HIV transmission in MSM in the Netherlands
van Sighem A, Bezemer D, Op de Coul E, BrangerJ, de Boer M, Reiss P

First and recurrent venous thrombosis in HIV patients of the Dutch ATHENA cohort
Rokx C, Borjas Howard J, Smit C, Wit F, Pieterman ED, Meijer K, Bierman W, Tichelaar V, Rijnders B

Longitudinal analysis shows no evidence for accelerated brain ageing in treated HIV
Cole JH, Caan MW, Underwood J, van Zoest R, De Francesco D, Winston A, Sabin C, Sharp DJ,  Reiss P

Integrase inhibitors are an independent risk factor for IRIS: an ATHENA cohort study
Wijting I, Rokx C, Wit F, Postma A, Hoepelman A, van der Ende I, Reiss P, Rijnders B

Vascular health and cerebral blood flow in perinatally HIV-infected children
Blokhuis C, Cohen S, Scherpbier HJ, Mutsaerts HJM, Meijers JC, Kootstra NA, Reiss P, Wit F, Teunissen CE, Pajkrt D

Central nervous system penetration of antiretroviral therapy in HIV-infected children
Hof MV, Blokhuis C, Cohen S, Scherpbier HJ, Wit F, Pistorius M, Kootstra NA, Teunissen CE, Mathot R, Pajkrt D

Poster presentations

Regional differences across Europe in advanced fibrosis and cirrhosis among HIV/HCV co-infected persons between 2010-2015
Amele S, on behalf of EuroSIDA

Variation in ART-coverage and virological suppression among HIV key populations
Laut K, on behalf of EuroSIDA

Oral presentations

  • Co- and multimorbidity in people aging with HIV
    Reiss, P.